These findings together with the frequently reduced levels of antithrombin III, protein S and C encountered in patients with liver disease (in our cohort 90.9%, 93.5% and 57.1%, respectively) highlight the difficult assessment of the hypercoagulable panel in the setting of cirrhosis and the need for this assessment to be performed by the Hematology Department. Here, SERPINC1 is linked to liver disorder.